Anti-Hypertensive Drugs - India

India

India is projected to witness significant growth in the Anti-Hypertensive Drugs market.
By 2024, the revenue in this market is expected to reach €192.00m in India.
Looking ahead, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 0.81%.
This growth trajectory is projected to result in a market volume of €199.90m by 2029 in India.
In comparison to the global market, United States is expected to generate the highest revenue in the Anti-Hypertensive Drugs market.
In 2024, United States is projected to generate a revenue of €11,400.00m.
India's growing middle-class population and increasing prevalence of hypertension are driving the demand for anti-hypertensive drugs in the country.

Key regions: Japan, India, Italy, Brazil, South Korea

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Anti-Hypertensive Drugs market in India has been steadily growing over the past few years, driven by various factors such as the increasing prevalence of hypertension, rising healthcare awareness, and the growing geriatric population.

Customer preferences: Indian customers are increasingly opting for anti-hypertensive drugs that are affordable and have minimal side effects. This has led to a rise in the demand for generic drugs, which are cheaper than branded drugs. Additionally, customers are also showing a preference for combination drugs, which offer the convenience of taking multiple medications in a single pill.

Trends in the market: One of the major trends in the Indian Anti-Hypertensive Drugs market is the increasing adoption of digital health technologies. This includes the use of telemedicine, mobile health apps, and other digital tools to improve patient outcomes and increase access to healthcare. Another trend is the growing focus on preventive healthcare, with an emphasis on lifestyle changes such as diet and exercise to manage hypertension.

Local special circumstances: India has a unique healthcare system, with a mix of public and private providers. While the public sector provides healthcare services at low or no cost, the private sector is more expensive but offers higher quality care. This has led to a divide in access to healthcare, with the majority of the population relying on the public sector. Additionally, the healthcare infrastructure in India is still developing, with a shortage of doctors and healthcare facilities in many areas.

Underlying macroeconomic factors: India is currently the world's fastest-growing major economy, with a rapidly expanding middle class and a growing consumer market. This has led to increased spending on healthcare, with the government investing in healthcare infrastructure and expanding access to healthcare services. Additionally, the rise of medical tourism in India has also contributed to the growth of the Anti-Hypertensive Drugs market, with many patients from around the world coming to India for affordable and high-quality medical treatment.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.